Evidence map›Paper›PMID 35983056›Full record

ArticleFrontiers in immunology2022

The HMGB1 (C106A) mutation inhibits IL-10-producing CD19

Mengru Liu, Jingwen Zhou, Rui Yin, Hui Yin, Yue Ding, Feng Ma, Li Qian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mengru LiuInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Jingwen ZhouInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Rui YinInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Hui YinInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Yue DingInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Feng MaCAMS Key Laboratory of Synthetic Biology Regulatory Elements, Institute of Systems Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Li QianInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Yangzhou University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNIntegrated Chinese Medicine (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory B cells have important roles in inflammation and autoimmune diseases. A newly discovered subpopulation of B cells with a CD19

Indexed as

B-Lymphocytes, RegulatoryHMGB1 ProteinSepsisSTAT3 Transcription FactorAnimalsAntigens, CD19Cell ProliferationInterleukin-10LipopolysaccharidesMiceMutationAntigens, CD19HMGB1 ProteinHMGB1 protein, mouseInterleukin-10LipopolysaccharidesStat3 protein, mouseSTAT3 Transcription FactorCD19hiFcγRIIbhi B cellsHMGB1IL-10sepsisSTAT3

Identifiers

PMID35983056
PMCPMC9378787
OpenAlexW4289518685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.